TW200637918A - Genetic variants predicting warfarin sensitivity - Google Patents
Genetic variants predicting warfarin sensitivityInfo
- Publication number
- TW200637918A TW200637918A TW094145510A TW94145510A TW200637918A TW 200637918 A TW200637918 A TW 200637918A TW 094145510 A TW094145510 A TW 094145510A TW 94145510 A TW94145510 A TW 94145510A TW 200637918 A TW200637918 A TW 200637918A
- Authority
- TW
- Taiwan
- Prior art keywords
- genetic variants
- polymorphism
- warfarin sensitivity
- warfarin
- promoter
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63883704P | 2004-12-21 | 2004-12-21 | |
| US67969405P | 2005-05-10 | 2005-05-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200637918A true TW200637918A (en) | 2006-11-01 |
| TWI334886B TWI334886B (en) | 2010-12-21 |
Family
ID=36602356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094145510A TWI334886B (en) | 2004-12-21 | 2005-12-21 | Genetic variants predicting warfarin sensitivity |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060166239A1 (zh) |
| EP (2) | EP1831402B1 (zh) |
| JP (1) | JP4516990B2 (zh) |
| KR (1) | KR101178463B1 (zh) |
| CN (1) | CN101142322B (zh) |
| AT (1) | ATE470725T1 (zh) |
| AU (1) | AU2005319028B2 (zh) |
| BR (1) | BRPI0519570A2 (zh) |
| CA (1) | CA2591840C (zh) |
| DE (1) | DE602005021821D1 (zh) |
| DK (1) | DK1831402T3 (zh) |
| ES (1) | ES2347167T3 (zh) |
| HK (1) | HK1117571A1 (zh) |
| MX (1) | MX2007007568A (zh) |
| NZ (1) | NZ556461A (zh) |
| PL (1) | PL1831402T3 (zh) |
| PT (1) | PT1831402E (zh) |
| TW (1) | TWI334886B (zh) |
| WO (1) | WO2006069339A2 (zh) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2575903T3 (es) | 2003-02-20 | 2016-07-04 | Mayo Foundation For Medical Education And Research | Métodos para seleccionar medicamentos antidepresivos |
| US8688385B2 (en) | 2003-02-20 | 2014-04-01 | Mayo Foundation For Medical Education And Research | Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype |
| ES2339710T5 (es) * | 2003-09-23 | 2017-10-05 | University Of North Carolina At Chapel Hill | Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K |
| US7445896B2 (en) * | 2004-10-18 | 2008-11-04 | University Of Washington | Methods and compositions for detecting VKORC1 single nucleotide polymorphisms |
| US20090325226A1 (en) | 2005-03-15 | 2009-12-31 | Stafford Darrel W | Methods and Compositions for Producing Active Vitamin K-Dependent Proteins |
| CA2911569C (en) * | 2005-11-29 | 2019-11-26 | Children's Hospital Medical Center | Optimization and individualization of medication selection and dosing |
| US8380539B2 (en) * | 2006-05-09 | 2013-02-19 | University Of Louisville Research Foundation, Inc. | Personalized medicine management software |
| US8039212B2 (en) * | 2007-11-05 | 2011-10-18 | Celera Corporation | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof |
| ES2927105T3 (es) * | 2008-10-20 | 2022-11-02 | Epitome Pharmaceuticals Ltd | Métodos y sistemas para mejorar la intervención farmacéutica en el control de la coagulación |
| KR101157135B1 (ko) * | 2008-12-29 | 2012-06-18 | 인제대학교 산학협력단 | 항응고제의 약물반응과 관련된 유전자의 변이 유전형 결정방법 |
| EP2233580A1 (en) * | 2009-03-05 | 2010-09-29 | The Ohio State University | Rapid genotyping of SNPs |
| JP5843487B2 (ja) * | 2010-06-01 | 2016-01-13 | アークレイ株式会社 | Ｖｋｏｒｃ１遺伝子の−１６３９番目の塩基の多型検出法、ならびにそのための核酸プローブおよびキット |
| US9631002B2 (en) | 2010-12-21 | 2017-04-25 | The University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin K-dependent proteins |
| EP2708895B1 (en) * | 2012-08-21 | 2019-05-08 | Industrial Technology Research Institute | Method for identifying more than one target nucleic acid contained in a sample |
| CN103173443B (zh) * | 2013-03-22 | 2016-08-24 | 卫生部北京医院 | 包括1300a>t突变的cyp2c9基因片段、所编码的蛋白质片段及其应用 |
| EP4119663A1 (en) | 2016-12-09 | 2023-01-18 | The Broad Institute, Inc. | Crispr effector system based diagnostics |
| US11174515B2 (en) | 2017-03-15 | 2021-11-16 | The Broad Institute, Inc. | CRISPR effector system based diagnostics |
| CN111742370A (zh) * | 2017-05-12 | 2020-10-02 | 密歇根大学董事会 | 个体和队列药理学表型预测平台 |
| AU2019213047A1 (en) | 2018-01-29 | 2020-07-16 | Massachusetts Institute Of Technology | CRISPR effector system based diagnostics |
| WO2020186223A1 (en) | 2019-03-14 | 2020-09-17 | The Broad Institute, Inc. | Sherlock assays for tick-borne diseases |
| CN110592206A (zh) * | 2019-09-11 | 2019-12-20 | 上海交通大学 | 一种利用rs9934438检测华法药效的试剂盒 |
| KR102506347B1 (ko) | 2021-05-11 | 2023-03-03 | 충북대학교 산학협력단 | 와파린 치료에 따른 출혈 부작용 위험 예측용 다형성 마커 및 이를 이용한 와파린 치료에 따른 출혈 부작용 위험 예측 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492115B1 (en) * | 2000-06-02 | 2002-12-10 | Dna Sciences Laboratories, Inc. | Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods |
| ES2339710T5 (es) * | 2003-09-23 | 2017-10-05 | University Of North Carolina At Chapel Hill | Células que coexpresan vitamina K reductasa y proteína dependiente de vitamina K y uso de las mismas para mejorar la productividad de dicha proteína dependiente de vitamina K |
| EP1809767B1 (en) * | 2004-10-18 | 2011-09-07 | University of Washington | Methods and compositions for predicting response to warfarin |
| US7445896B2 (en) * | 2004-10-18 | 2008-11-04 | University Of Washington | Methods and compositions for detecting VKORC1 single nucleotide polymorphisms |
| US20080005732A1 (en) * | 2006-05-11 | 2008-01-03 | Coon Robert F | Method and System for Integrating Software Update Services with Software Applications |
-
2005
- 2005-12-21 NZ NZ556461A patent/NZ556461A/en unknown
- 2005-12-21 AT AT05855433T patent/ATE470725T1/de active
- 2005-12-21 TW TW094145510A patent/TWI334886B/zh active
- 2005-12-21 DK DK05855433.8T patent/DK1831402T3/da active
- 2005-12-21 DE DE602005021821T patent/DE602005021821D1/de active Active
- 2005-12-21 PT PT05855433T patent/PT1831402E/pt unknown
- 2005-12-21 MX MX2007007568A patent/MX2007007568A/es active IP Right Grant
- 2005-12-21 ES ES05855433T patent/ES2347167T3/es active Active
- 2005-12-21 CN CN2005800485213A patent/CN101142322B/zh active Active
- 2005-12-21 WO PCT/US2005/046869 patent/WO2006069339A2/en active Application Filing
- 2005-12-21 BR BRPI0519570-5A patent/BRPI0519570A2/pt active Search and Examination
- 2005-12-21 EP EP05855433A patent/EP1831402B1/en active Active
- 2005-12-21 EP EP10165009A patent/EP2246445A1/en not_active Withdrawn
- 2005-12-21 AU AU2005319028A patent/AU2005319028B2/en active Active
- 2005-12-21 US US11/316,406 patent/US20060166239A1/en not_active Abandoned
- 2005-12-21 KR KR1020077016947A patent/KR101178463B1/ko active IP Right Grant
- 2005-12-21 JP JP2007548549A patent/JP4516990B2/ja active Active
- 2005-12-21 CA CA2591840A patent/CA2591840C/en active Active
- 2005-12-21 PL PL05855433T patent/PL1831402T3/pl unknown
-
2008
- 2008-08-07 HK HK08108714.0A patent/HK1117571A1/xx unknown
-
2010
- 2010-03-12 US US12/722,672 patent/US20110236885A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4516990B2 (ja) | 2010-08-04 |
| WO2006069339A2 (en) | 2006-06-29 |
| PT1831402E (pt) | 2010-09-10 |
| AU2005319028B2 (en) | 2010-09-16 |
| PL1831402T3 (pl) | 2010-12-31 |
| HK1117571A1 (en) | 2009-01-16 |
| WO2006069339A3 (en) | 2006-10-12 |
| US20060166239A1 (en) | 2006-07-27 |
| TWI334886B (en) | 2010-12-21 |
| KR20080005179A (ko) | 2008-01-10 |
| EP1831402B1 (en) | 2010-06-09 |
| DE602005021821D1 (de) | 2010-07-22 |
| ATE470725T1 (de) | 2010-06-15 |
| MX2007007568A (es) | 2008-03-11 |
| CN101142322B (zh) | 2011-09-21 |
| NZ556461A (en) | 2009-12-24 |
| EP1831402A2 (en) | 2007-09-12 |
| WO2006069339A8 (en) | 2010-06-03 |
| CA2591840C (en) | 2012-07-10 |
| ES2347167T3 (es) | 2010-10-26 |
| CN101142322A (zh) | 2008-03-12 |
| JP2008523844A (ja) | 2008-07-10 |
| DK1831402T3 (da) | 2010-09-20 |
| US20110236885A1 (en) | 2011-09-29 |
| AU2005319028A1 (en) | 2006-06-29 |
| EP2246445A1 (en) | 2010-11-03 |
| CA2591840A1 (en) | 2006-06-29 |
| BRPI0519570A2 (pt) | 2009-01-27 |
| KR101178463B1 (ko) | 2012-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200637918A (en) | Genetic variants predicting warfarin sensitivity | |
| IL182519A0 (en) | Methods and compositions for predicting drug responses | |
| Shah et al. | Personalized medicine: is it a pharmacogenetic mirage? | |
| WO2007070280A3 (en) | Use of deletion polymorphisms to predict, prevent, and manage histoincompatibility | |
| WO2010018601A3 (en) | Genetic variants predictive of cancer risk | |
| TW200636075A (en) | Detection of nucleic acid variation by cleavage-amplification method | |
| NZ591613A (en) | Polymorphic marker rs965513 for risk assessment of thyroid cancer | |
| GB2477705A (en) | Methods and compositions of molecular profiling for disease diagnostics | |
| ATE408032T1 (de) | Esr1 und gebärmutterhalskrebs | |
| DK1718967T3 (da) | Metoder til at detektere Lp-PLA2 aktivitet | |
| CL2011003129A1 (es) | Procedimiento para determinar riesgo de padecer enfermedad cardiovascular que comprende determinar la presencia de polimorfismos de un solo nucleotido (snp) | |
| WO2008033427A3 (en) | Compositions and methods for detection of lysosomal storage disease | |
| WO2010004591A3 (en) | Genetic variants for breast cancer risk assessment | |
| DK1842920T3 (da) | Celler der co-udtrykker K-vitaminreduktase og K-vitaminafhængigt protein, samt anvendelse deraf til at forbedre produktiviteten af det K-vitaminafhængige protein | |
| MX2010005960A (es) | Biomarcadores de braf. | |
| PL1730315T3 (pl) | Polimorfizmy w genie NOD2/CARD15 | |
| WO2007103816A3 (en) | Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection | |
| Zhang et al. | Detection of CYP2E1, a genetic biomarker of susceptibility to benzene metabolism toxicity in immortal human lymphocytes derived from the Han Chinese population | |
| EA201291228A1 (ru) | Биомаркер для детекции высокогорной адаптации и высокогорного отека легких | |
| WO2006099259A3 (en) | Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof | |
| NZ604125A (en) | Prediction of hcv viral kinetics in interferon-free treatment | |
| WO2006044686A3 (en) | Methods and compositions for predicting drug responses | |
| WO2005112568A3 (en) | Haplotype markers and methods of using the same to determine response to treatment | |
| EA201171171A1 (ru) | Генетические маркеры степени тяжести рассеянного склероза | |
| ATE523602T1 (de) | Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen |